|
|
News Breaks | | | | January 16, 2013 | | 10:04 EDT |  | STZ, ABBV, NVE, PERI, GXP | On The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: AbbVie (ABBV) initiated with a Buy at Jefferies... AbbVie (ABBV) initiated with an Outperform at Wells Fargo... Great Plains Energy (GXP) initiated with a Buy at SunTrust... NV Energy (NVE) initiated with a Neutral at SunTrust... Perion Network (PERI) initiated with a Buy at Benchmark Co... Constellation Brands (STZ) initiated with a Buy at Buckingham. | |
|
News For ABBV;GXP;NVE;STZ;PERI From The Last 14 Days Check below for free stories on ABBV;GXP;NVE;STZ;PERI the last two weeks. |
|
|
| June 19, 2013 | | 07:58 EDT |  | ABBV | Dr Reddy's sued over thyroid injection patent, Economic Times reports
Drug maker AbbVie (ABBV) is suing Dr Reddy's Lab (RDY) for allegedly infringing the former's patented drug Zemplar on six counts concerning three patents, reports the Economic Times.Reference Link | | | 06:26 EDT |  | PERI | Perion weakness due to profit taking, skepticism, says Benchmark Co.
Benchmark Co. attributes the recent pullback in shares of Perion Network to profit taking and ongoing investor skepticism regarding the affiliate search space. The firm sees no reason for the pullback given the stabilization in the search market and possible upcoming catalysts. It lowered its price target for shares to $18 from $20 but keeps a Buy rating on the name. | | | June 17, 2013 | | 08:17 EDT |  | ABBV | AbbVie announces preliminary results in Phase 1 study of ABT-199
 Subscribe for More Information | | | June 13, 2013 | | 05:14 EDT | | ABBV | AbbVie presents first study of MTX when used with Humira for RA treatment
AbbVie announced the results from the CONCERTO trial, the first randomized, controlled trial assessing different predefined doses of methotrexate, or MTX, in combination with Humira for the treatment of moderate to severe rheumatoid arthritis, or RA. CONCERTO shows that at week 26 of treatment, a statistically significant increasing trend was observed in the proportion of patients achieving low disease activity with an increasing dose of MTX when used with open-label Humira. Results were presented at the European League Against Rheumatism 2013 Congress in Madrid, Spain. The primary objective of CONCERTO was to determine a dose-response pattern of MTX in combination with Humira in MTX and biologic-naive patients with active moderate to severe RA for less than 1 year. Patients were randomized into four treatment arms, receiving 40 mg of open-label Humira every other week in combination with weekly oral MTX at 2.5 mg, 5 mg, 10 mg or 20 mg. | | | June 12, 2013 | | 11:45 EDT |  | GXP | Great Plains Energy management to meet with DA Davidson
Meetings to be held in San Francisco on June 17 and in Portland, OR on June 18 hosted by DA Davidson. | | | June 10, 2013 | | 07:40 EDT | | ABBV | Leerink's biotech analyst holds analyst/industry conference call on ASCO
Subscribe for More Information | | | June 7, 2013 | | 16:07 EDT | | STZ | Constellation completes acquisition of Grupo Modelo's U.S. beer business
Constellation Brands (STZ) announced that it has completed its acquisition of Grupo Modelo's U.S. beer business from Anheuser-Busch InBev (BUD) for approximately $4.75B. The transaction includes full ownership of Crown Imports LLC which provides Constellation with complete, independent control of all aspects of the U.S. commercial business; a state-of-the-art brewery in Nava, Mexico; exclusive perpetual brand license in the U.S. to import, market and sell Corona and the Modelo brands Crown currently sells and the freedom to develop brand extensions and innovations for the U.S. market. With the close of the acquisition, Constellation begins to operate as one company with two divisions: a beer division and a wine and spirits division. A brewery operations group has also been established to manage the expansion and integration of the Nava brewery. Constellation plans to invest $500M-$600M during the next three years to expand the facility to double its current capacity to meet projected demand for products in the U.S. | | | June 5, 2013 | | 12:59 EDT | | STZ | Constellation says has agreement in principle with DoJ, Mexican Antitrust unit
Constellation Brands says it has reached two key milestones for regulatory approvals for the Modelo transaction including an agreement in principle with the U.S. Department of Justice and approval by the Mexican Antitrust Commission. At this time, the closing of the transaction is expected to occur around the end of Constellation’s Q1 or shortly thereafter. The purchase price for the combined transaction is $4.75B. This includes $1.85B for the remaining interest in Crown, and $2.9B for the brewery and perpetual brand rights which is based on an initial assumed EBITDA of $310M representing the profit stream from Modelo’s sales of beer to Crown Imports for 2012. Comments made in slide presentation ahead of company's investor meeting. | | | 08:16 EDT | | STZ | Constellation Brands to host investor meeting
Subscribe for More Information | |
|
|
|
|
|
|
